T umor vaccines seek to induce a CTL response against tumors. To achieve efficient tumor cell killing, different strategies have been evaluated for inducing both CD4 + Th cell and CD8 + T cell responses against tumor Ags. Attention has focused on exploiting dendritic cells (DCs) as professional APCs capable of presenting exogenous Ag not only on MHC class II, but also on MHC class I, a process termed cross-presentation. Because of feasibility issues, most vaccination protocols have relied on in vitro-generated DCs loaded with tumor Ag as an individualized tumor vaccine (1, 2) . As DC activation has been recognized to be of critical importance for the induction of productive immune responses, DC maturation was included in vaccination protocols (3, 4) . However, the production of DC vaccines is labor-and costintensive, as cytapheresis may be required and vaccines have to be manufactured individually for each patient. A promising strategy circumventing the need of ex vivo DC generation and manipulation is targeting vaccines directly to DCs in vivo (5, 6) . Moreover, the development of cell-free vaccines for off-the-shelf use will make vaccines accessible to more patients and reduce manufacturing costs (7) . Challenges for the design of effective cancer vaccines are DCspecific Ag targeting, facilitating MHC class I epitope processing, and identifying adjuvants that activate DCs in vivo for generating and activating effector T cells as well as innate effector cells.
An important parameter for vaccine design is the choice of tumor Ag and its physical properties (i.e., peptide, protein, DNA or RNA). Most clinical trials have evaluated synthetic MHC class I-and/or MHC class II-restricted peptides derived from tumor Ags. A drawback of using preformed peptides is restricting treatment to patients with a limited number of MHC haplotypes. This limitation can be circumvented by using full-length proteins, which 1) contain multiple MHC class I and MHC class II epitopes, 2) can be used without knowledge of the patient's MHC haplotype, and 3) are presented for prolonged periods on MHC molecules as compared with peptides (8) . A shortcoming may be that DCs cross-present soluble protein inefficiently on MHC class I. However, this limitation can be circumvented by using Ab-Ag conjugates that target DC surface receptors involved in Ag uptake, such as Fc receptors (8) (9) (10) (11) , members of the C-type lectin receptor family including CD205, the mannose receptor, and DC-specific intracellular adhesion molecule 3-grabbing nonintegrin (12) (13) (14) .
Alternatively, Ag can be formulated with chemically defined delivery systems, such as ISCOMATRIX adjuvant, which is derived from the immunostimulating complex (ISCOM) first described by Morein et al. (15) . They observed enhanced immune responses to protein formulated with a mixture of saponin, phospholipids, and cholesterol that forms cage-like structures (15) . ISCOMATRIX vaccines that contain only a purified fraction of quillaia saponin were shown to be safe, well tolerated, and highly immunogenic in humans, generating Ab and T cell responses (16) . An ISCOM vaccine has the Ag incorporated into the structure during manufacture, whereas an ISCOMATRIX vaccine is made by mixing Ag with preformed ISCOMATRIX adjuvant. Both entities are otherwise identical. Interestingly, ISCOM vaccines facilitate cross-presentation by DCs via translocation of Ag from endosomes into the cytosol (8, 17) . Moreover, ISCOMA-TRIX adjuvant-based tumor vaccines containing full-length tumor Ag-induced humoral and cellular immune responses in mouse models (18, 19) as well as in cancer patients (20) . Taken together, these studies demonstrate the high clinical potential of ISCO-MATRIX adjuvant in tumor vaccines.
Little is known about the immunological effects mediated by ISCOM and ISCOMATRIX vaccines on DCs and other leukocyte populations in vivo. Understanding the mechanisms of action underlying these vaccines will be important for optimal use in the clinic and further optimization. In this study, we investigated the effects of ISCOMATRIX adjuvant and an ISCOM vaccine containing the model Ag OVA on cytokine milieu and on phenotype as well as function of innate and adaptive immune effector cells in vaccine site-draining lymph nodes (VDLNs). We further studied Ag uptake and presentation by distinct DC populations in VDLNs and analyzed the induction of cellular immune responses in wildtype mice and mice in which distinct DC populations were depleted.
Materials and Methods

Cell culture media and reagents
Primary cells were cultivated in RPMI 1640 media supplemented with heatinactivated 10% FCS (Life Technologies BRL, Paisley, U.K.), 2 mM Lglutamine, penicillin (100 U/l), streptomycin (0.1 mg/ml), 100 mM nonessential amino acids, 1 mM sodium pyruvate (all PAA, Linz, Austria), and 50 mM 2-ME. The OVA/ISCOM vaccine was generated by associating palmitified OVA (Sigma-Aldrich, St. Louis, MO), which in some experiments was labeled with the fluorochrome Alexa 488, into the ISCOM structure by formulation in the presence of ISCOPREP saponin, phospholipid, and cholesterol, as previously described (17) . ISCOMATRIX adjuvant was made in the same way without the OVA. The H2-K brestricted peptide OVA 257-264 (SIINFEKL) was purchased from Jerini Peptide Technologies (Berlin, Germany). CpG-containing oligodeoxynucleotide 1826 (CpG-ODN 1826 ; InvivoGen, San Diego, CA) and Pam3-Cys (InvivoGen) were used at 5 mg, LPS (LPS 0111:B4; Chondrex, Redmond, WA) at 1 mg, and aluminum hydroxide (Aluhydrogel; Superfos Biosector, Frederikssund, Denmark) at 100 mg per injection. IFA (Bacto/ Difco, Mount Pritchard, Australia) was used at a 50:50 dilution of the stock solution.
Mice and vaccinations
Female C57BL/6 mice, 6-8 wk old, were purchased from Harlan Winkelmann (Borchen, Germany). Langerin-diphtheria toxin receptor (DTR)/ enhanced GFP knock-in mice on C57BL/6 background expressing a DTR and enhanced GFP under the Langerin promoter were provided by Dr. B.E. Clausen (21) . For depletion of Langerin + DCs we administered 500 ng DT (Sigma-Aldrich) 1 d prior to immunization. A week later DT injection was repeated to keep Langerin + DCs absent throughout the experiment. For depletion of CD11c + DCs, transgenic mice expressing the DTR fused with GFP under control of the CD11c promoter (CD11c-DTR mice) were used (22) . Irradiated C57BL/6 mice were reconstituted with bone marrow from CD11c-DTR transgenic mice, rendering DTR expressing CD11c + DCs from hematopoietic origin sensitive to DT treatment. Reconstituted mice were administered three doses of DT every 3 d from day 0. An 80% depletion of CD11c + DCs was confirmed before the first immunization.
Transgenic OT-1 mice were provided by Prof. T. Brocker (Department of Immunology, University of Munich, Munich, Germany). Animal experiments were approved by the local regulatory agencies. For vaccination, mice were injected s.c. into the lower hind leg with 50-100 ml PBS containing either OVA (30 mg) with or without adjuvants, ISCOMATRIX adjuvant (5 mg), or OVA/ISCOM vaccine (containing 0.3 mg OVA/5 mg ISCOM). Vaccination was repeated on day 7 (prime-boost regimen).
LN preparation
Mice were anesthetized with 1-chlor-2,2,2-trifluorethyl-difluormethyl ether (Forene; Abbott, Wiesbaden, Germany) and killed by cervical dislocation. The VDLNs were removed and processed into single-cell suspensions by passing through a 70-mm cell strainer. Adjusted cell numbers were processed for phenotypic and functional analysis.
mAbs and flow cytometry
For flow cytometry, cell suspensions were incubated for 20 min at 4˚C with the following Abs: CD3ε (clone 145-2C11), CD4 (clone GK1.5), CD8a (clone 53-6.7), CD11b (clone M1-70), CD11c (clone HL3), IL-12p40 (clone C15.6), CD19 (clone 1D3), CD86 (clone GL1), NK1.1 (clone PK136; all from BD Biosciences, San Jose, CA); CD69 (clone H1.2F3) and IFN-g (clone XMG1.2; both from Caltag Laboratories, Carlsbad, CA); and Ly6G (clone RB6-8C5; eBioscience, San Diego, CA) and MHC class II (clone NIMR-4; SouthernBiotech, Birmingham, AL). Samples were acquired on a FACSCalibur (BD Biosciences, Heidelberg, Germany) and analyzed using FlowJo version 7.2.1 (Tree Star, Ashland, OR).
Intracellular cytokine staining and pentamer staining
To assess cytokine expression by DCs, NK cells, and NKT cells, cell suspensions of VDLNs were incubated with 1 mg/ml brefeldin A (Fluka, Munich, Germany) for 4 h at 37˚C and subsequently stained for surface markers, fixed with 2% paraformaldehyde, incubated with mAb against IL12p40 or IFN-g in 0.5% saponin in PBS, and analyzed by flow cytometry. To measure OVA-specific CTL response, PBMCs of 100-200 ml peripheral blood were stimulated with SIINFEKL peptide (1 mg/ml) for 1 h at 37˚C before addition of 1 mg/ml brefeldin A. Three hours later IFN-g intracellular cytokine staining (ICS) was performed as described above. Alternatively, the number of OVA-specific CTLs was determined using SIINFEKL/H-2K b pentamer (ProImmune, Oxford, U.K.) together with mAbs against CD8a, CD19, and NK1. 
Cytokine measurement
VDLNs were shock frozen in liquid nitrogen, processed using mortar and pestle, and lysed with 50 ml protein lysis buffer (Bio-Rad, Munich, Germany). Samples were vortexed for 30 s, centrifuged for 15 min at 12,000 3 g and 4˚C, and supernatant was used for cytokine analysis. Samples were adjusted to 2 mg protein/ml as determined by Bradford assay (Bio-Rad). IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, TNF-a, IFN-g, and GM-CSF concentrations were determined by a Bio-Rad multiplex suspension array according to the manufacturer's instructions. For Western blot analysis, adjusted protein samples were separated by SDS-PAGE. IL1b was detected using a primary goat anti-mouse IL-1b Ab (R&D Systems) followed by a secondary HRP-coupled anti-goat Ab (Santa Cruz Biotechnology, Heidelberg, Germany). b-actin served as a loading control. IL-1b in supernatants of bone marrow-derived DCs was measured by ELISA (BD Biosciences). DCs (10 6 cells/ml) were treated with 200 ng/ml LPS for 2 h before addition of 10 mM caspase-1 inhibitor z-YVAD-fmk (Calbiochem, Darmstadt, Germany) for 1 h followed by 6 h incubation with 5 mg/ml ISCOMATRIX adjuvant.
In vitro cross-presentation assay
Total DCs were enriched by Percoll density gradient centrifugation (1.077 g/cm 3 ; Biochrom) after mechanical and enzymatic processing of spleens. Untouched CD8a + DCs were obtained by combining the Ab mixture of the mouse DC isolation kit (Invitrogen) with biotinylated anti-CD4 (clone RM4-5) and anti-B220 (clone RA3-6B2; both from BioLegend). Finally, cells were enriched by magnetic separation using streptavidin-coupled beads (Invitrogen). Purity was usually .90% as determined by flow cytometry. CD8a
+ DCs were incubated with the indicated amounts of OVA or OVA/ISCOM vaccine for 90 min and washed four times in serum-free media. Finally, 2. 
In vivo T cell proliferation assay
Splenocytes from OT-1 mice were suspended at 5 3 10 7 cells/ml in PBS/ 0.1% BSA containing 10 mM CFSE (Invitrogen/Molecular Probes, Eugene, OR) for 10 min at 37˚C. Cells were washed twice with cold RPMI 1640/10% FCS followed by two washes in PBS. CFSE-labeled OT-1 cells (2 3 10 6 ) in 200 ml PBS were injected into the tail vein of mice that were vaccinated once with OVA, OVA/ISCOM vaccine, or PBS on the same day. Two days later, peripheral blood was collected and CFSE dilution of proliferating OT-1 CD8 + T cells was analyzed by flow cytometry.
Ex vivo cross-presentation by DC subpopulations
Twenty-four hours after s.c. immunization, VDLNs were processed into a single-cell suspension with a collagenase/DNAase solution. DCs were enriched by Nycodenz density gradient centrifugation (1.082 g/cm 3 ; Nycomed Pharma, Oslo, Norway), followed by depletion of non-DCs and plasmacytoid DCs with an Ab mixture containing anti-CD3 (clone KT3), anti-Thy-1 (cloneT24/31.7), anti-CD19 (clone ID6), anti-Gr1 (clone RB6-8C5), and Ter-119 and magnetic beads coated with anti-rat IgG (Dynal beads M450; Invitrogen). Enriched DCs were stained with mouse antiCD11c-allophycocyanin, anti-CD8-FITC, and anti-CD205-PE (BD Biosciences) and FACS sorted into three DC subpopulations (FACSAria; BD Biosciences). A purity of .93% was obtained routinely. DCs were cultured with CFSE-labeled OT-I cells at 10,000:50,000 DC/OT-I cell ratio, and proliferation of OT-I cells was measured 48 h later by flow cytometry.
In vivo cytotoxicity assay
Mice were injected i.v. with a mixture of splenocytes differentially labeled with CFSE (2, 20, or 200 nM) loaded with 1, 10, or 100 nM SIINFEKL peptide, respectively, and unloaded spleen cells were labeled with 10 mM chloromethyl-benzoyl-aminotetramethyl-rhodamine (Invitrogen/Molecular Probes). A total of 12 3 10 6 cells per mouse were injected, consisting of a mixture containing each target cell population. Inguinal LNs draining the immunization site were collected 24 h after injection of target cells. Presence of viable injected target cells was determined using exclusion by 7-aminoactinomycin D. Percentage killing was calculated using the formula as described (24) .
Tumor induction
The OVA-expressing thymoma EG7 was obtained from the American Type Culture Collection. The B16-OVA melanoma was a gift from Dr. J. Hess (Erlangen, Germany). PancOVA was generated from the pancreatic cancer line Panc02 (18) . For tumor induction, 10 6 tumor cells in 100 ml PBS were injected s.c. into the flank of age-matched vaccinated and unvaccinated mice. Tumor size was determined using a caliper, and mice were culled when the tumor size reached 200 mm 2 .
Statistical analysis
A Student t test was applied to reveal significant differences between groups. A p value , 0.05 was accepted as the level of significance.
Results
Subcutaneous injection of an OVA/ISCOM vaccine and ISCOMATRIX adjuvant leads to recruitment and activation of innate and adaptive immune effector cells in VDLNs
To characterize the immunostimulatory effect of ISCOM vaccines on leukocyte populations in vivo, we injected mice s.c. with OVA, the OVA/ISCOM vaccine, or ISCOMATRIX adjuvant without Ag and removed VDLNs for analysis of leukocyte composition and activation marker expression. Both ISCOMATRIX adjuvant and the OVA/ISCOM vaccine induced a visible enlargement of the VDLNs, reaching a maximum after 24 h (Supplemental Fig. 1A) . At 24 h the total cell number had increased 5-to 6-fold as compared with VDLNs of mice injected with PBS or OVA alone (Fig.  1A ). FACS analysis of VDLN cell suspensions revealed a significant increase of B cell, CD4 + T cell, and CD8 + T cell numbers (Fig. 1B) ; overall, the CD4/CD8 ratio was not affected (data not shown). Additionally, we observed a dramatic increase in the numbers of NK1.1 + CD3 2 NK cells (13-fold) and NK1.1 + CD3 + NKT cells (11-fold) (Fig. 1C) . Interestingly, VDLNs contained a population with high sideward light scatter property and coexpression of Ly6G + and CD11b + , which was absent in control LNs (Fig. 1D) . These cells could be identified as granulocytes using H&E staining (Supplemental Fig. 1B) . Importantly, this immune stimulatory effect was limited to the VDLNs, since contralateral LNs and spleens did not differ in cell number or composition from control animals (data not shown).
Next, we characterized the activation status of innate and adaptive immune effector cells in VDLNs by measuring CD69 and intracellular IFN-g expression. The OVA/ISCOM vaccine induced significant CD69 upregulation on B cells, CD4 + T cells, and CD8 + T cells ( Fig. 2A) . Additionally, we observed upregulation of CD69 expression and IFN-g production by NK cells and NKT cells (Fig.  2B) . Overall, we observed no difference between ISCOMATRIX adjuvant alone and the OVA/ISCOM vaccine with regard to (Fig. 1E ). The importance of DC activation for CTL induction has been demonstrated in DC-based therapy studies (3, 4) . In this respect, Th1 responses are required, which are dependent on the production of Th1-driving cytokines by DCs, such as IL-12 (26 (Fig. 3A) .
To evaluate the capacity of DCs to cross-present the Ag in vivo, we transferred CFSE-labeled T cells from OT-1 mice, which recognize the H2-K b -restricted epitope SIINFEKL, into mice vaccinated with either soluble OVA (30 mg) or the OVA/ISCOM vaccine (containing 0.3 mg OVA). OT-1 T cell proliferation and IFN-g production were assessed after 3 and 10 d in the VDLNs by flow cytometry. As shown in Fig. 3B , the OVA/ISCOM vaccine induced a potent T cell proliferative and IFN-g response. In contrast, even 100-fold higher concentrations of soluble protein induced only minor T cell proliferation. Interestingly, crosspresenting capacity of APCs in VDLNs was lasting for a period of up to 10 d after vaccination. To assess which DC population was most efficient in CD8 + T cell activation, we isolated LNresident CD8a + DEC205 + DCs, LN-resident CD8a 2 DEC205
2 DCs, and migratory CD8a 2 DEC205 + DCs from VDLNs by FACS and cocultured the DC subsets with CFSE-labeled OT-I T cells. This experiment revealed that CD8a + DCs were most efficient in cross-presenting the OVA/ISCOM vaccine in vivo (Fig. 3C) . Cross-presentation efficacy was further studied with splenic CD8a + DCs pulsed with either soluble OVA or OVA/ISCOM in vitro. These experiments confirmed highly effective crosspresentation of the vaccine Ag by this DC subset and further demonstrated a .100-fold Ag-sparing effect as compared with soluble Ag (Fig. 3D) .
The OVA/ISCOM vaccine induces high levels of IL-1b and IL-6 as well as a mixed Th1/Th2 cytokine profile in VDLNs
To evaluate the cytokine response mediated by the ISCOM vaccine, we vaccinated mice and removed the VDLNs after 6, 12, and 24 h. VDLNs of mice injected with either PBS or OVA served as controls. Concentrations of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, GM-CSF, and TNF-a were measured by multiplex assay. Strikingly, high levels of IL-1b and IL-6 were produced in VDLNs as early as 6 h after injection of the vaccine, indicative of an early inflammatory response (Fig. 4A) . Additionally, the vaccine induced the production of GM-CSF and IL-12p40, as well as low levels of IL-4 and IL-5, indicative of a mixed Th1/Th2 type response. No significant changes in IL-2, IL-10, IL-12p70, or TNF-a production were observed. To confirm that IL-1b was secreted in its bioactive form (17 kDa) we performed Western blot analysis of VDLN lysates. As shown in Fig. 4B , p17 was detected in VDLNs but not control LNs (PBS). IL-1b secretion in response to the ISCOM vaccine was confirmed in LPS-primed DCs in vitro and could be blocked with z-YVAD, an inhibitor of caspase-1 (Fig. 4C) . Thus, ISCOM vaccines induce caspase-1-dependent cleavage of pro-IL1b to active IL-1b in DCs.
The OVA/ISCOM vaccine induces priming of CTL capable of tumor cell killing
We analyzed the vaccine-induced immune response using a primeboost regimen in which mice were vaccinated twice with OVA/ ISCOM vaccine (0. Fig. 2A) . Depletion of Langerin + APCs had no impact on CTL priming or cytotoxic activity in vivo, indicating that these DC subsets are dispensable for ISCOM vaccinemediated CTL induction (Fig. 5C, 5D ). These data strengthen the hypothesis that CTL priming by ISCOM vaccines is predominantly mediated by conventional DCs, with other APCs playing a less important role.
The functional activity of the CTL was studied in an in vivo cytotoxicity assay using adoptively transferred SIINFEKL-pulsed and CFSE-labeled splenocytes. Specific target cell lysis was 80 and 60% on days 10 and 35 after the second vaccination, respectively, indicative of T cell memory induction (Fig. 6A) . No significant killing 
Discussion
ISCOMATRIX adjuvant-based vaccines hold promise for generating effective CTL responses against tumors (19) . In this study, we investigated mechanisms of action of ISCOMATRIX adjuvant and an OVA/ISCOM vaccine. We used the ISCOM vaccine rather than the ISCOMATRIX vaccine to be sure that the Ag and adjuvant were associated, thereby enabling labeling of the Ag to track the formulation. We found that ISCOM vaccines 1) induce potent immune activation in VDLNs, 2) effectively target Ag to DCs in vivo, 3) induce DC maturation and IL-12 production in vivo, 4) facilitate Ag cross-presentation by CD8a + DCs, and 5) mediate a cellular immune response leading to tumor protection and T cell memory induction.
Immune activation by an ISCOMATRIX vaccine has been demonstrated by lymphatic cannulation in sheep with the transient appearance of proinflammatory cytokines in efferent lymph, including IFN-g, IL-6, IL-8, and IL-1b (27) . Consistent with this report, we found high levels of bioactive IL-1b and IL-6 in VDLNs in mice. Additionally, we found increased levels of IL-5 and IL-12, indicative of a mixed Th1/Th2 response. IL-1b is a proinflammatory cytokine that mediates recruitment of leukocytes to sites of inflammation and the secretion of other proinflammatory cytokines, such as IL-6. The secretion of bioactive IL1b is regulated by caspase-1-activating inflammasome complexes, such as the NLRP3 inflammasome (28) . Interestingly, we observed secretion of bioactive IL-1b by DCs incubated with ISCOMA-TRIX adjuvant in vitro, which occurred in a caspase-1-dependent manner. Assessing the role of different inflammasome types, such as the NLRP3 inflammasome, on the adjuvant properties of ISCOMATRIX adjuvant is the focus of ongoing studies.
The immunostimulatory effect of ISCOMATRIX adjuvant was further demonstrated by the recruitment of activated innate and adaptive effector cells to VDLNs. The increase of total cell composition within VDLNs was predominantly due to recruitment of B cells and T cells, expressing high levels of the early activation marker CD69. Additionally, a marked increase of NK cells and NKT cells producing IFN-g as well as an influx of granulocytes was observed. A cross-talk between NK cells and DCs has been suggested to play an important role in anti-tumor immunity. Mature DCs can induce IFN-g expression in NK cells (29) . Reciprocally, NK cells have the capacity to induce DC maturation and IL-12 production (30) . A similar interplay between granulocytes and DCs leading to DC maturation and enhanced Ag presentation has been reported (31, 32 that cross-presenting capacity was mainly attributed to CD8a + DCs, at least during the first 24 h. Moreover, deletion of both Langerhans cells and dermal Langerin + DCs in Langerin-DTR mice with the DT protocol used in our study (35) did not influence CTL cross-priming. In contrast, deletion of CD11c + DCs in mice with bone marrow from CD11c-DTR mice almost completely abrogated CTL induction. Taken together, these data indicate that conventional CD8a + DCs are the main cell type mediating ISCOM vaccine-induced CTL responses. Whether other DC types or even granulocytes, which effectively engulfed the ISCOM vaccine (see Supplemental Fig. 2C ), play a role in transporting the vaccine Ag from the injection site to the VDLNs should be investigated in further studies (36, 37) . Of note, the efficacy of the ISCOM vaccine in priming CTL responses was striking with an average of 8.5% of Ag-specific CD8 + T cells in peripheral blood after only two vaccinations. Side-by-side comparisons with other adjuvant systems proved the high efficacy of ISCOM vaccines. Even at a 100-fold higher Ag concentration, combinations of OVA with TLR ligands (TLR2, TLR4, or TLR9), IFA, or alum were far less effective in cross-priming a CTL response. Additionally, we could demonstrate effective CTL responses in three different tumor models, in which immunization with an ISCOM vaccine using a prime-boost regimen mediated complete tumor protection against OVA-expressing tumor cells.
In conclusion, ISCOMATRIX adjuvant combines characteristics of a potent immune modifier with effective Ag delivery to DCs in vivo and leads to the induction of a strong cellular immune response. ISCOMATRIX adjuvant-based vaccines have shown promising results in patients with cancer (20) . The data presented in this study support our understanding of the underlying cellular mechanism of ISCOM and ISCOMATRIX vaccines and will allow us to enhance vaccine efficacy for inducing effective anti-tumor immune responses.
